

Ohad Oren

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9431744/ohad-oren-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

155
citations

6
h-index

12
g-index

21
ext. papers

248
ext. citations

8.9
avg, IF

3.89
L-index

#	Paper	IF	Citations
17	Curbing Unnecessary and Wasted Diagnostic Imaging. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 245-246	27.4	40
16	Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. <i>The Lancet Digital Health</i> , 2020 , 2, e486-e488	14.4	35
15	Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2020 , 22, 66	6.3	25
14	Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>American Journal of Cardiology</i> , 2020 , 125, 1920-1926	3	22
13	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008688	6.4	10
12	Incidental Imaging Findings in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 603-604	27.4	9
11	Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience). <i>American Journal of Cardiology</i> , 2019 , 124, 1669-1673	3	3
10	Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease. <i>Current Oncology Reports</i> , 2020 , 22, 87	6.3	2
9	Cost-Effectiveness Analyses of FDA-Approved Drugs for Cancer Indications, 2015-2017. <i>Blood</i> , 2018 , 132, 5833-5833	2.2	1
8	Cardiovascular Safety Assessment in Cancer Drug Development.. <i>Journal of the American Heart Association</i> , 2021 , 10, e024033	6	1
7	Solutions to Reduce Unnecessary Imaging-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 2243	27.4	
6	Recognizing "diagnostic futility" - stopping earlier to protect patients. <i>American Journal of Hematology</i> , 2020 , 95, 580-582	7.1	
5	Drug Value Along the Treatment Continuum in Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 4728-4728	2.2	
4	Investigation-Based Drug Value Framework in Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 2262-2262	2.2	
3	Geographic Trends in Clinical Trials in Lymphoma, 1997-2017. <i>Blood</i> , 2018 , 132, 3554-3554	2.2	
2	Cardiovascular Prevention in Individuals at High Risk of Developing Cancer. <i>JACC: CardioOncology</i> , 2020 , 2, 527-531	3.8	
1	Improving Communication of Incidental Imaging Findings: Transforming Uncertainty Into Opportunity. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2753-2756	6.4	

